je.st
news
Tag: phase
VCO: CRO3650B-LF Features Ultra-Low Phase Noise While Covering 3600 To 3700 MHz
2014-11-14 04:09:06| rfglobalnet Home Page
Z-Communications, Inc. announces a new RoHS compliant VCO (Voltage Controlled Oscillator) model CRO3650B-LF. The CRO3650B-LF is guaranteed to cover 3600 to 3700 MHz within a tuning voltage range of 0.5 to 4.5 Vdc. This high performance VCO features a spectrally clean signal of -101 dBc/Hz @ 10 kHz offset and a typical tuning sensitivity of 60 MHz/V.
Tags: features
phase
noise
covering
ICON Cleared For Next Development Phase
2014-11-14 02:32:24| rfglobalnet Home Page
NASA has officially confirmed the Ionospheric Connection Explorer, or ICON, mission, clearing it to move forward into the development phase. ICON will explore a swath of Earth's atmosphere where weather close to the ground impacts the dynamic space environment above in unexpected ways.
Tags: development
phase
icon
cleared
ADM Opens First Phase Of Integrated Food-Ingredient Plant In Tianjin, China
2014-11-13 01:43:45| foodingredientsonline Home Page
Today, Archer Daniels Midland Company officially opened the sweetener-manufacturing portion of its integrated food manufacturing complex with a ribbon-cutting ceremony at the port of Tianjin in North China, on the Yellow Sea
Tags: china
phase
integrated
plant
Final phase of CARAT 2014 exercise begins in Brunei
2014-11-12 01:00:00| Naval Technology
The final phase of the 20th annual Cooperation Afloat Readiness and Training (CARAT) exercise has started at the Maura Naval Base in Brunei.
Tags: final
phase
exercise
begins
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients
2014-11-11 14:00:00| Merck.com - Research & Development News
Dateline City: BOSTON Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively) with or without ribavirin (RBV) in treatment-nave and previously-treated (with peg-interferon/ribavirin [PR]) patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection -- the C-WORTHy study (Parts A and B). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
treatment
phase
Sites : [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] next »